Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etanercept in arthritis.

D L Scott1

  • 1Department of Rheumatology, GKT School of Medicine, Weston Education Centre, Kings College, London, UK. janice.jimenez@kcl.ac.uk

International Journal of Clinical Practice
|February 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.

Arthritis research & therapy·2020
Same author

Secular changes in functional disability, pain, fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-analysis.

Seminars in arthritis and rheumatism·2019
Same author

The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life.

Seminars in arthritis and rheumatism·2019
Same author

Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis.

RMD open·2016
Same author

Improving medication adherence in rheumatoid arthritis (RA): a pilot study.

Psychology, health & medicine·2015
Same author

Treat to target in managing inflammatory arthritis.

British journal of hospital medicine (London, England : 2005)·2015

Etanercept effectively treats rheumatoid arthritis by blocking tumour necrosis factor-alpha (TNF-alpha). This biologic therapy reduces disease activity and joint damage, offering a new option for patients.

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Tumour necrosis factor-alpha (TNF-alpha) is a key inflammatory cytokine involved in autoimmune diseases.
  • TNF-alpha signals through receptors like the type 2 TNF receptor (p75).
  • Rheumatoid arthritis (RA) is a chronic inflammatory condition characterized by joint damage.

Purpose of the Study:

  • To evaluate the efficacy and safety of etanercept in treating rheumatoid arthritis.
  • To understand etanercept's mechanism of action as a TNF-alpha inhibitor.
  • To assess etanercept's role in managing other inflammatory arthropathies.

Main Methods:

  • Etanercept, a soluble TNF-receptor fusion protein, was administered subcutaneously.
  • Clinical trials assessed etanercept's impact on disease activity and joint damage in RA patients.

Related Experiment Videos

  • Comparative analysis included monotherapy versus combination therapy with methotrexate.

    • Main Results:

    • Etanercept demonstrated significant efficacy in reducing disease activity and limiting progressive joint damage in RA.
    • The drug is effective in psoriatic arthritis and ankylosing spondylitis.
    • Combination therapy with methotrexate appeared most effective.

    Conclusions:

    • Etanercept is an effective and safe biologic treatment for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    • Caution is advised regarding potential reactivation of tuberculosis and other safety concerns.
    • Etanercept's cost and optimal treatment positioning are subjects of ongoing discussion.